Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
出版年份 2013 全文链接
标题
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
作者
关键词
-
出版物
PHARMACOGENOMICS JOURNAL
Volume 14, Issue 2, Pages 120-129
出版商
Springer Nature
发表日期
2013-03-26
DOI
10.1038/tpj.2013.10
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
- (2012) M. J. Lamas et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of theUGT1A1andCYP2A6Polymorphisms on Clinical Activity
- (2012) Yoon Hee Choi et al. ONCOLOGY
- Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients
- (2011) Katerina Shulman et al. CANCER
- Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms
- (2011) Y. Okuyama et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Regimen Selection for First-line FOLFIRI and FOLFOX Based on UGT1A1 Genotype and Physical Background is Feasible in Japanese Patients with Advanced Colorectal Cancer
- (2011) H. Ishida et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results
- (2010) S. R. Park et al. ANNALS OF ONCOLOGY
- UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy
- (2010) E Martinez-Balibrea et al. BRITISH JOURNAL OF CANCER
- UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer
- (2010) Yu Sunakawa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Dose-dependent association between UGT1A1∗28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
- (2010) Zhe-Yi Hu et al. EUROPEAN JOURNAL OF CANCER
- Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
- (2010) Howard L. McLeod et al. JOURNAL OF CLINICAL ONCOLOGY
- Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
- (2010) Valérie Boige et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
- (2010) B Glimelius et al. PHARMACOGENOMICS JOURNAL
- Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors
- (2009) Crystal S. Denlinger et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on theUGT1A1*28polymorphism
- (2009) Shoichi Hazama et al. CANCER SCIENCE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial
- (2009) Michael S. Braun et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan
- (2009) Erika Cecchin et al. JOURNAL OF CLINICAL ONCOLOGY
- UGT1A1*28genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan
- (2009) Roberta Ferraldeschi et al. PHARMACOGENOMICS
- UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
- (2009) Christoph Schulz et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
- (2008) E Rouits et al. BRITISH JOURNAL OF CANCER
- UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
- (2008) D M Kweekel et al. BRITISH JOURNAL OF CANCER
- UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
- (2008) Chun-Yu Liu et al. CANCER
- Pharmacogenetics in colorectal cancer: a systematic review
- (2008) Silvia Funke et al. PHARMACOGENOMICS
- Methodological quality of pharmacogenetic studies: Issues of concern
- (2008) Andrea L. Jorgensen et al. STATISTICS IN MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now